Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

498 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Clinical trials in multiple sclerosis: milestones.
Zhang Y, Salter A, Cutter G, Stuve O. Zhang Y, et al. Among authors: salter a. Ther Adv Neurol Disord. 2018 Jul 9;11:1756286418785499. doi: 10.1177/1756286418785499. eCollection 2018. Ther Adv Neurol Disord. 2018. PMID: 30034537 Free PMC article. Review.
Evolution of clinical trials in multiple sclerosis.
Zhang Y, Salter A, Wallström E, Cutter G, Stüve O. Zhang Y, et al. Among authors: salter a. Ther Adv Neurol Disord. 2019 Feb 21;12:1756286419826547. doi: 10.1177/1756286419826547. eCollection 2019. Ther Adv Neurol Disord. 2019. PMID: 30833985 Free PMC article. Review.
Cladribine tablets after treatment with natalizumab (CLADRINA) - rationale and design.
Sguigna PV, Hussain RZ, Okai A, Blackburn KM, Tardo L, Madinawala M, Korich J, Lebson LA, Kaplan J, Salter A, Manouchehri N, Stuve O. Sguigna PV, et al. Among authors: salter a. Ther Adv Neurol Disord. 2024 Apr 4;17:17562864241233858. doi: 10.1177/17562864241233858. eCollection 2024. Ther Adv Neurol Disord. 2024. PMID: 38585373 Free PMC article.
A one-year prospective, randomized, placebo-controlled, quadruple-blinded, phase II safety pilot trial of combination therapy with interferon beta-1a and mycophenolate mofetil in early relapsing-remitting multiple sclerosis (TIME MS).
Remington GM, Treadaway K, Frohman T, Salter A, Stüve O, Racke MK, Hawker K, Agosta F, Sormani MP, Filippi M, Frohman EM. Remington GM, et al. Among authors: salter a. Ther Adv Neurol Disord. 2010 Jan;3(1):3-13. doi: 10.1177/1756285609355851. Ther Adv Neurol Disord. 2010. PMID: 21180632 Free PMC article.
A randomized, blinded, parallel-group, pilot trial of mycophenolate mofetil (CellCept) compared with interferon beta-1a (Avonex) in patients with relapsing-remitting multiple sclerosis.
Frohman EM, Cutter G, Remington G, Gao H, Rossman H, Weinstock-Guttman B, Durfee JE, Conger A, Carl E, Treadaway K, Lindzen E, Salter A, Frohman TC, Shah A, Bates A, Cox JL, Dwyer MG, Stüve O, Greenberg BM, Racke MK, Zivadinov R. Frohman EM, et al. Among authors: salter a. Ther Adv Neurol Disord. 2010 Jan;3(1):15-28. doi: 10.1177/1756285609353354. Ther Adv Neurol Disord. 2010. PMID: 21180633 Free PMC article.
498 results